Treatment with XCT790 significantly reduced the mRNA level of GREM1 as well as that of KLK3, one of the ERRα target genes, in MDA-MB-453 and SKBR3 breast cancer cells (Fig. 4e). This evidence concerns the gene KLK3 and breast carcinoma.